Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1. Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality

Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality Prescrire IN ENGLISH - Spotlight '' Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality'', 1 May 2020 {1} {1} {1} | | > > > Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |    (...) |   |   |   |   |   |   |   |  Spotlight In the May issue of Prescrire International: Dulaglutide (Trulicity°) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality FREE DOWNLOAD In patients with type 2 diabetes who had a modest elevation of HbA1c, a recent trial suggested that addition of dulaglutide to hypoglycaemic therapy slightly reduced the risk of stroke, but did not reduce either all-cause mortality

2020 Prescrire

2. Management of Hypoglycaemia in Children and Young People with Type 1 Diabetes

and caregivers, especially when there is a high risk of severe hypoglycaemia. Education on administration of glucagon is essential Blood glucose monitoring should be performed prior to exercise, and extra carbohydrates should be consumed based on the blood glucose level and the expected intensity and duration of the exercise REFERENCE 1. NICE (2015) Diabetes (type 1 and type 2) in children and young people. NICE guideline NG18 www.nice.org.uk/guidance/ng18 2. ISPAD Clinical Practice Consensus Guidelines 2014 (...) Management of Hypoglycaemia in Children and Young People with Type 1 Diabetes ssociation of Children’s Diabetes Clinicians Clinicians Version 4, May 2018 Review 2021 Authors: SM Ng, E Williams, F Ackland, C Burren, J Edge, E Hind, A McAulay, Bill Lamb 1 SETTING Children and young people with diabetes mellitus PATIENTS Children and young people with diabetes mellitus Guidance • Definition of hypoglycaemia in children with diabetes is a blood glucose 4.0mmol/L, Retest 20-30 minutes later

2020 British Society for Paediatric Endocrinology and Diabetes

3. Care of the Well Child-Newly Diagnosed with Type 1 Diabetes

published ahead of print September 6, 2012, doi:10.2337/dc12-0720 15. Canadian Agency for Drugs and Technologies in Health. Systematic review of use of blood glucose test strips for the management of diabetes mellitus. [June 2010]. Available from.www.cadth.ca/products/cadth-overviews/vol-1.../vol-1-issue-1-01 16. NICE (2015) Diabetes (type 1 and type 2) in children and young people. NICE guideline NG18 www.nice.org.uk/guidance/ng18 Version 4, Dec 2019 Review 2022 Authors: J Chizo Agwu, SM Ng, A Timmis (...) care in children at diagnosis of tyoe 1 diabetes mellitus. Cochrane Database of systematic reviews2007, issue 2. Art No: CD004099. DOI: 10.1002/14651858.CD004009.pub 2 19. Home based care improved glycaemic control and was cost effective in children with type 1 diabetes. Dougherty G, Schriffin A, White D, et al. Pediatrics 1999 Jan; 103: 122-8. 20. The delivery of ambulatory diabetes care to children and adolescents with diabetes. Pihoker C, Forsander G, Wolfsdorf J, Klingensmith GJ. Pediatric

2020 British Society for Paediatric Endocrinology and Diabetes

4. Metabolic surgery for the treatment of type 2 diabetes: A network meta-analysis of randomized controlled trials Full Text available with Trip Pro

Metabolic surgery for the treatment of type 2 diabetes: A network meta-analysis of randomized controlled trials Metabolic Surgery for the Treatment of Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine (...) Diabetes Obes Metab Actions . 2020 Apr 3. doi: 10.1111/dom.14045. Online ahead of print. Metabolic Surgery for the Treatment of Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials , , , Affiliations Expand Affiliations 1 Diabetology, Careggi Hospital, Florence, Italy. 2 University of Florence, Florence, Italy. PMID: 32243058 DOI: Item in Clipboard Metabolic Surgery for the Treatment of Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials Barbara Cresci et al

2020 EvidenceUpdates

5. Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial Full Text available with Trip Pro

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial Differential Glycaemic Control With Basal Insulin Glargine 300 U/mL Versus Degludec 100 U/mL According to Kidney Function in Type 2 Diabetes: A Subanalysis From the BRIGHT Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) : Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Apr 3. doi: 10.1111/dom.14043. Online ahead of print. Differential Glycaemic Control With Basal Insulin Glargine 300 U/mL Versus Degludec 100 U/mL According to Kidney Function in Type 2 Diabetes: A Subanalysis From the BRIGHT Trial , , , , , , , , , Affiliations Expand Affiliations 1 Diabetes Centre, Institute for Clinical

2020 EvidenceUpdates

6. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial (...) : ( ) Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Apr 15;dc192452. doi: 10.2337/dc19-2452. Online ahead of print. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2

2020 EvidenceUpdates

7. Combined continuous glucose monitoring and subcutaneous insulin infusion versus self-monitoring of blood glucose with optimized multiple injections in people with type 1 diabetes: A randomized crossover trial Full Text available with Trip Pro

, , , , , , Affiliations Expand Affiliations 1 Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy. 2 Diabetes Unit, Careggi Teaching Hospital, Florence, Italy. PMID: 32166907 DOI: Item in Clipboard Combined Continuous Glucose Monitoring and Subcutaneous Insulin Infusion Versus Self-Monitoring of Blood Glucose With Optimized Multiple Injections in People With Type 1 Diabetes: A Randomized Crossover Trial Ilaria Dicembrini et al. Diabetes Obes Metab . 2020 . Show details (...) Combined continuous glucose monitoring and subcutaneous insulin infusion versus self-monitoring of blood glucose with optimized multiple injections in people with type 1 diabetes: A randomized crossover trial Combined Continuous Glucose Monitoring and Subcutaneous Insulin Infusion Versus Self-Monitoring of Blood Glucose With Optimized Multiple Injections in People With Type 1 Diabetes: A Randomized Crossover Trial - PubMed This site needs JavaScript to work properly. Please enable it to take

2020 EvidenceUpdates

8. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial

Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 Apr 21;141(16):1295-1306. doi: 10.1161/CIRCULATIONAHA.119.044865. Epub 2020 Mar 5. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial

2020 EvidenceUpdates

9. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9)

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9) A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9) - PubMed This site needs JavaScript to work (...) , in Adults With Type 2 Diabetes (Onset 9) , , , , , , , , , , Affiliations Expand Affiliations 1 Mountain Diabetes and Endocrine Centre, Asheville, NC mountaindiabetes@msn.com. 2 Novo Nordisk A/S, Søborg, Denmark. 3 Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, South Korea. 4 Novo Nordisk A/S, Aalborg, Denmark. 5 Santojanni Hospital and CENUDIAB, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina. 6 Institute

2020 EvidenceUpdates

10. Insulin pumps for people with Type 1 Diabetes

Insulin pumps for people with Type 1 Diabetes 1 Driving better decision-making in healthcare Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes Technology Guidance from the MOH Medical Technology Advisory Committee Published on 23 March 2020 Guidance recommendations The Ministry of Health Medical Technology Advisory Committee has recommended: ? Continuous subcutaneous insulin infusion therapy (CSII) and its consumables as a treatment option for adults and children (...) with type 1 diabetes mellitus: o who use multiple daily injections of insulin (MDI) to achieve target HbA1c but result in the person experiencing disabling hypoglycaemia, where disabling hypoglycaemia is defined as the repeated and unpredictable occurrence of hypoglycaemia that results in persistent anxiety about recurrence and is associated with a significant adverse effect on quality of life (QoL); or o who have unacceptably high HbA1c (i.e. at 8.5% or above) on MDI despite a high level of care, where

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

11. Insulin glargine/lixisenatide (Suliqua) - for the treatment of adults with type 2 diabetes mellitus

Insulin glargine/lixisenatide (Suliqua) - for the treatment of adults with type 2 diabetes mellitus 1 Published 13 April 2020 1 SMC2235 insulin glargine plus lixisenatide (Suliqua®), 100 units/mL plus 50 microgram/mL and 100 units/mL plus 33 micrograms/mL solution for subcutaneous injection in pre-filled pens Aventis Pharma Limited, trading as Sanofi 06 March 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission insulin glargine/lixisenatide (Suliqua ® ) is accepted for restricted use within NHSScotland. Indication under review: In combination with metformin for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose-lowering medicinal product or with basal

2020 Scottish Medicines Consortium

12. Early Childhood Antibiotic Treatment for Otitis Media and Other Respiratory Tract Infections Is Associated With Risk of Type 1 Diabetes: A Nationwide Register-Based Study With Sibling Analysis Full Text available with Trip Pro

Infections Is Associated With Risk of Type 1 Diabetes: A Nationwide Register-Based Study With Sibling Analysis Mona-Lisa Wernroth et al. Diabetes Care . 2020 . Show details Diabetes Care Actions . 2020 Mar 4;dc191162. doi: 10.2337/dc19-1162. Online ahead of print. Authors , , , , , , Affiliations 1 Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden. 2 Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. 3 Clinical (...) often with statistically nonsignificant associations. Conclusions: Dispensed prescription of antibiotics, mainly for acute otitis media and respiratory tract infections, in the 1st year of life is associated with an increased risk of type 1 diabetes before age 10, most prominently in children delivered by cesarean section. © 2020 by the American Diabetes Association. Similar articles Örtqvist AK, Lundholm C, Kieler H, Ludvigsson JF, Fall T, Ye W, Almqvist C. Örtqvist AK, et al. Version 2. BMJ. 2014

2020 EvidenceUpdates

13. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk Full Text available with Trip Pro

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk To investigate the effects of semaglutide versus comparators on major adverse cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] and nonfatal stroke) and hospitalization for heart failure (HF) in the SUSTAIN (subcutaneous semaglutide) and PIONEER (oral semaglutide) trials across subgroups of varying CV risk.Post hoc analyses of individual (...) semaglutide showed consistent effects on MACE versus comparators across varying CV risk. No effect of semaglutide on MACE was observed in subjects with prior HF.© 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

2020 EvidenceUpdates

14. Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study Full Text available with Trip Pro

Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study To compare the safety and efficacy of U500-R delivered by a novel, specifically designed U500-R insulin pump with U-500R delivered by multiple daily injections (MDI).The phase 3 VIVID study randomized people with type 2 diabetes to U-500R by continuous subcutaneous insulin infusion (CSII) or MDI. Participants (aged 18-85 years) had HbA1c ≥7.5 (...) <0.001); fasting plasma glucose, -33.9 mg/dL (-1.9 mmol/L) with CSII and 1.7 mg/dL (0.09 mmol/L) with MDI (difference - 35.6 mg/dL [-2.0 mmol/L], P <0.001); total daily dose, 2.8 U with CSII and 51.3 U with MDI (P < 0.001). Weight changes and rates of documented symptomatic and severe hypoglycaemia were similar between groups; the CSII group had a higher rate of nocturnal hypoglycaemia.In type 2 diabetes requiring high doses of insulin, both methods of U-500R delivery lowered HbA1c. However, the CSII

2020 EvidenceUpdates

15. Association Between the Use of Antidepressants and the Risk of Type 2 Diabetes Mellitus: A Large, Population-Based Cohort Study in Japan (Abstract)

Association Between the Use of Antidepressants and the Risk of Type 2 Diabetes Mellitus: A Large, Population-Based Cohort Study in Japan This study aimed to reveal the associations between the risk of new-onset type 2 diabetes mellitus and the duration of antidepressant use and the antidepressant dose, and between antidepressant use after diabetes onset and clinical outcomes.In this large-scale retrospective cohort study in Japan, new users of antidepressants (exposure group) and nonusers (...) (nonexposure group), aged 20-79 years, were included between 1 April 2006 and 31 May 2015. Patients with a history of diabetes mellitus or receipt of antidiabetes treatment were excluded. Covariates were adjusted by using propensity score matching; the associations were analyzed between risk of new-onset type 2 diabetes and the duration of antidepressant use/dose of antidepressant in the exposure and nonexposure groups by using Cox proportional hazards models. Changes in glycated hemoglobin (HbA1c) level

2020 EvidenceUpdates

16. A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice Full Text available with Trip Pro

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII durability trial (NCT02501161). Participants (N = 1012 (...) ) with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs) were randomized 1:1 to open-label IDegLira or IGlar U100. Visits were scheduled at weeks 1, 2, 4 and 12, and every 3 months thereafter. After 26 weeks, glycated haemoglobin (HbA1c) reductions were greater with IDegLira versus IGlar U100 (-21.5 vs. -16.4 mmol/mol [-2.0 vs. -1.5%]), as was the percentage of participants achieving HbA1c <53 mmol/mol (78.7% vs. 55.7%) and HbA1c targets without weight gain and/or hypoglycaemia

2020 EvidenceUpdates

17. Efficacy of 10-20-30 training versus moderate-intensity continuous training on HbA1c, body composition and maximum oxygen uptake in male patients with type 2 diabetes: A randomized controlled trial (Abstract)

Efficacy of 10-20-30 training versus moderate-intensity continuous training on HbA1c, body composition and maximum oxygen uptake in male patients with type 2 diabetes: A randomized controlled trial To compare the efficacy of 10-20-30 training versus moderate-intensity continuous training (MICT) on HbA1c, body composition and maximum oxygen uptake (V˙O2 max) in male patients with type 2 diabetes (T2D).Fifty-one male participants with T2D were randomly assigned (1:1) to a 10-20-30 (N = 26

2020 EvidenceUpdates

18. Sotagliflozin with insulin for treating type 1 diabetes

an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sotagliflozin with insulin for treating type 1 diabetes (TA622) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about sotagliflozin 6 3 Committee discussion 7 Clinical management 7 Experience of people (...) -and- conditions#notice-of-rights). Page 3 of 211 1 Recommendations Recommendations 1.1 Sotagliflozin with insulin is recommended as an option for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m 2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy, only if: sotagliflozin is given as one 200 mg tablet daily they are on insulin doses of 0.5 units/kg of body weight/day or more and they have completed a structured education programme

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

19. Comprehensive Type 2 Diabetes Management Algorithm - EXECUTIVE SUMMARY

Comprehensive Type 2 Diabetes Management Algorithm - EXECUTIVE SUMMARY Comprehensive Type 2 Diabetes Management Algorithm (2020) - EXECUTIVE SUMMARY | American Association of Clinical Endocrinologists search Search Resources BACK Offering Guidance Through the Latest Science on Bone-Related Disorders Treat your diabetes patients with expert precision. Offering Guidance Through the Latest Science on Lipid Conditions Education Menu FEATURED EMBR AACE 2020 EMBR AACE , the AACE 29 th Annual (...) to enhancing our members’ knowledge, education, and practice management skills so they can focus on providing the highest quality of patient care. We also advocate for the profession to create understanding of the value of our community to patients, organizations and the public. search Breadcrumb Comprehensive Type 2 Diabetes Management Algorithm (2020) - EXECUTIVE SUMMARY Footer Navigation Partner With Us Join us to develop an open dialogue between industry and foster AACE in the furtherance of patient

2020 American Association of Clinical Endocrinologists

20. Management of Type 2 Diabetes Mellitus

Management of Type 2 Diabetes Mellitus Quality Department Guidelines for Clinical Care Ambulatory Diabetes Mellitus Guideline Team Team Leaders Connie J Standiford, MD General Internal Medicine Sandeep Vijan, MD General Internal Medicine Team Members Hae Mi Choe, PharmD College of Pharmacy R Van Harrison, PhD Medical Education Caroline R Richardson, MD Family Medicine Jennifer A Wyckoff, MD Metabolism, Endocrinology & Diabetes Consultants Martha M Funnell, MS, RN, CDE Diabetes Research (...) proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient. Management of Type 2 Diabetes Mellitus Patient population. Adults Objectives. To reduce morbidity and mortality by improving adherence to important recommendations for preventing, detecting, and managing diabetic

2020 University of Michigan Health System